<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637676</url>
  </required_header>
  <id_info>
    <org_study_id>2802</org_study_id>
    <nct_id>NCT00637676</nct_id>
  </id_info>
  <brief_title>Tunneled Pleural Catheter in Partially Entrapped Lung</brief_title>
  <official_title>Randomized Trial of Tunneled Pleural Catheter Versus Standard Chest Tube in Management of Malignant Pleural Effusion in Patients With Partial Entrapment of the Lung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open randomized, prospective, single center; parallel group trial to compare efficiency
      and safety of PleurX-Pleural Catheter versus standard surgical treatment in patients with
      malignant pleural effusion and partial entrapment of the lung.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with malignant pleural effusions undergo VATS-procedure. In the intraoperative
      finding of a partially entrapped lung, patients are randomized in 2 groups.

      Arm 1: Insufflation of talc and insertion of a (standard) drainage which will be removed 4-7
      days after surgery.

      Arm 2: Insufflation of talc and insertion of a (standard) drainage which will be removed 4-7
      days after surgery. Additionally, a subcutaneous tunneled catheter will be inserted and will
      remain in situ

      Follow up period is 3 Months

      Primary objective is the comparison of quality of life between the 2 arms.

      Secondary objective is the reliability of the subcutaneous tunnelled catheter in practice as
      well as function and dysfunction of the drainage system. Clinical parameters (respiratory
      function measured as FEV1 and vital capacity, recurrent pleural effusion, infection, need for
      relief of effusion or pleuracentesis) are observed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>global quality scale QL2</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical parameters (respiratory function measured as FEV1 and vital capacity, recurrent pleural effusion, infection, need for relief of effusion or pleuracentesis)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Pleural Effusion</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of PleurX-Pleural catheter plus talc pleurodesis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>talc pleurodesis, no implantation of PleurX-Pleural catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VATS, Talc-Pleurodesis, tunneled pleural drainage</intervention_name>
    <description>poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Device: PleurX-Pleural Catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VATS, Talc-pleurodesis</intervention_name>
    <description>poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter</description>
    <arm_group_label>2</arm_group_label>
    <other_name>no PleurX-Pleural Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One-sided malignant pleural effusion, first occurrence, or following repeated
             pleuracentesis

          -  History of dyspnea relieved after pleuracentesis

          -  Patient is suitable for VATS

          -  Surgery is indicated by diagnostic necessity

          -  Ability of subject to understand character and individual consequences of clinical
             trial

          -  Written informed consent must be available before enrolment in the trial

          -  For women with childbearing potential, adequate contraception.

          -  Histological proven pleural carcinosis by immediate sectioning

          -  Intraoperative: partial entrapment of the lung

        Exclusion Criteria:

          -  Prior lobectomy or pneumonectomy on the affected side

          -  The patient is not operable for general reasons or Karnofsky performance score &lt; 50

          -  Intraoperative suspicion of a pleural empyema

          -  Chylothorax

          -  Prior attempts at pleurodesis

          -  Intended or prior intrapleural chemotherapy or radiotherapy

          -  Pregnancy and lactation

          -  Participation in other competing clinical trials and observation period of competing
             trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Hoffmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik, University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thoraxklinik, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Putnam JB Jr, Walsh GL, Swisher SG, Roth JA, Suell DM, Vaporciyan AA, Smythe WR, Merriman KW, DeFord LL. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg. 2000 Feb;69(2):369-75.</citation>
    <PMID>10735665</PMID>
  </reference>
  <reference>
    <citation>Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J. 2007 Oct;30(4):759-62. Epub 2007 Jun 13.</citation>
    <PMID>17567670</PMID>
  </reference>
  <reference>
    <citation>Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006 Feb;129(2):362-8.</citation>
    <PMID>16478853</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>September 22, 2011</last_update_submitted>
  <last_update_submitted_qc>September 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Felix JF Herth</investigator_full_name>
    <investigator_title>Head</investigator_title>
  </responsible_party>
  <keyword>malignant pleural effusion</keyword>
  <keyword>subcutaneous tunneled drainage</keyword>
  <keyword>talc pleurodesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

